Convalife Advances Breakthrough Oncology Combination Therapies with Right-6D Pipeline Strategy, Files IPO Prospectus
In recent years, with the accumulation of years of drug R&D experience by domestic pharmaceutical companies and the continuous introduction of outstanding overseas innovative drug talent, the R&D capabilities of Chinese pharmaceutical companies for innovative drugs have gradually upgraded, and an increasing number of enterprises now possess strong capabilities in developing high-quality innovative drugs. Meanwhile, a series of successive policies introduced by the Chinese government in recent years regarding the evaluation and approval of drug registrations have further stimulated enthusiasm for innovative drug R&D within the domestic healthcare industry, leading to the rapid emergence of a large number of innovative drug companies.
The aggregation of talent and the continuous iteration and updating of technology have driven rapid development and upgrading in the medical industry. We can observe that R&D strategies among domestic pharmaceutical companies are transitioning from mere “Me-too/Me-better” approaches to “Fast-follow” and “Best-in-class” models, with some even beginning to pursue “First-in-class” innovations. This is a welcome and encouraging trend.
Nevertheless, we must also acknowledge that basic scientific research in China remains relatively weak and is currently unable to provide sufficient innovative support for the overall development of the biopharmaceutical industry. In this context, to secure a foothold in China’s new drug R&D market and even compete in the global arena, it is particularly crucial to fully unlock the development potential of projects, select appropriate indications, and implement differentiated strategic positioning.
Convalife (Shanghai) Health Technology Co., Ltd. (“Convalife”) is a new drug R&D enterprise that has a deep understanding of new drug development strategies. Driven by robust R&D capabilities, sophisticated new drug development strategies, and exceptional execution by its management team, Convalife has experienced rapid growth over the past two years. It has garnered favor and substantial financial support from numerous listed companies, including WuXi Biologics and Menovo Pharmaceutical, as well as prominent investment institutions such as Haihui Capital, Qiandao Fund, Yingke Capital, and Tengchuang Investment. Within three years of its establishment, the company completed three rounds of financing totaling over RMB 100 million and is currently in its Series B financing round.
So, what is the secret to Fukang’s rapid development?
Fukang, established in 2018, is a clinical-stage innovative drug R&D enterprise based in China with a global outlook. The company is guided by unmet clinical medication needs in China and worldwide, primarily targetingTumorIn the disease area, design and develop original new drugs with "First-in-Class" or "Best-in-Class" potential, while simultaneously developing next-generation bispecific antibody biologics and small molecule drugs.
The company has established the “Right-6D” new drug R&D strategy, which focuses on: Right Target Definition, Right Tissue Delivery, Right Safety Guidance, Right Patient Assessment, Right Combination Design, and Right Commercial Potential Deployment. The entire R&D process applies the SMART principles. By setting clear R&D objectives, enhancing their measurability and achievability, clarifying interdependencies among multiple goals, and defining time-bound targets, this approach improves product development efficiency and ensures the smooth progress of R&D activities.
The highlights of Fukang’s product pipeline layout are mainly reflected in three aspects:
First, the product pipeline covers a wide range and has the potential to become blockbuster products.Fukang’s product targets are currently focused on three major areas: tumor drug resistance, DNA repair, and tumor immunity. Its R&D pipeline covers most solid tumors with an urgent need for innovative treatment solutions both domestically and internationally, including breast cancer, prostate cancer, pancreatic cancer, liver cancer, gastric cancer, and lung cancer. Once successful, these targets have strong potential to become blockbuster drugs.
Second, differentiated positioning in the selection of indications for the product pipeline.Taking CVL218, a PARP inhibitor developed by Fukang, as an example for introduction.
When Fukang initially planned the indication research for CVL218, it took into account that PARP inhibitors already marketed in China had been approved for the treatment of ovarian cancer, as well as the indication selections made by some domestic pharmaceutical companies for similar products. Consequently, Fukang decided to develop other indications with potential for success, including prostate cancer, pancreatic cancer, breast cancer, gastrointestinal tumors, and glioma.
"Due to its impressive preclinical and clinical data, CVL218 has the potential to become a 'Best in Class' new drug and has received support from the National Major Special Projects three times."
Dr. Shen Xiaokun, FukangAccording to VCBeat, CVL218 demonstrates significantly superior selectivity, solubility, and stability compared to marketed drugs such as Olaparib, Rucaparib, and Niraparib. It overcomes the drawbacks of first-generation PARP inhibitors, including poor solubility, low bioavailability, limited tissue distribution, and significant adverse reactions. As a second-generation PARP inhibitor, it also holds substantial advantages in physicochemical properties over AZD-5305, which has recently entered Phase I clinical trials, and currently maintains a lead in clinical development progress.
Notably, CVL218 is currently the only PARP inhibitor worldwide capable of effectively crossing the blood-brain barrier. Therefore, Fukang has strategically positioned CVL218 for development in the indication of glioma. CVL218 is currently in Phase II clinical trials. Fukang estimates that the global market for PARP inhibitors (PARPi) will exceed USD 8 billion in 2023, with the domestic market in China surpassing RMB 24 billion, making the future prospects for CVL218 highly promising.
Third, synergistic layout across product pipelines with multi-dimensional development.A review of Fukang’s current product pipeline reveals that the company has both designed and developed original innovative drugs with “First-in-Class” or “Best-in-Class” potential, and pursued the development of next-generation bispecific antibodies and even trispecific antibody therapeutics. The epigenetic inhibitor N008 offers therapeutic advantages for both hematologic malignancies and solid tumors. These pipeline assets are synergistic, enabling multi-dimensional development in the future.
B006, one of Fukang’s “First-in-Class” projects, is a next-generation bispecific antibody drug. Preclinical data show that B006 exhibits superior in vivo antitumor efficacy compared to the combination of two monoclonal antibodies, PD-L1 inhibitor and bevacizumab. B006 is primarily indicated for the treatment of solid tumors such as liver cancer, gastric cancer, and non-small cell lung cancer. Another “First-in-Class” project is CVL237, a dual highly selective PI3K inhibitor whose global development rights were acquired by Fukang. CVL237 has completed Phase I clinical trials at the MD Anderson Cancer Center, achieving an objective response rate (ORR) of 50%.
Dr. Shen Xiaokun believes that,The future trend in oncology treatment is to pursue combination therapies, thereby enhancing drug efficacy and unlocking therapeutic potential.Fukang has already initiated clinical research on combination therapies. For instance, it is pursuing a “triple-drug combination” regimen comprising the PARP inhibitor CVL218, the VEGF inhibitor fruquintinib, and a PD-1 inhibitor. “We aim to develop a breakthrough therapeutic product through combination treatment, establishing it as a first-line oncology treatment regimen. The ‘triple-drug combination’ approach currently represents the latest global trend in cancer therapy, with AstraZeneca also conducting similar studies. The three drug classes we have selected offer favorable safety profiles, potentially yielding greater clinical benefits for patients. If clinical outcomes prove promising, we are poised to achieve a ‘leapfrog’ advancement on the international stage.”
The ability to delve deeply into clinical needs, keenly perceive market dynamics, and strategically differentiate or synergize the product pipeline undoubtedly relies on the company’s leadership’s profound understanding and insight into the market. However, the rapid advancement of the company’s pipeline is even more indebted to the diligent efforts of Fukang’s outstanding clinical development and R&D teams working behind the scenes.
Fukang’s clinical development and R&D teams are composed of industry elites with many years of hands-on experience in the pharmaceutical sector, boasting extensive expertise in both scientific research and industrial applications. For example,Ms. Zhang Hong, CMO of FukangWith nearly 25 years of experience in drug development and related fields across China and the United States, she earned an MBA from Cardiff Business School in the UK. Prior to returning to China in 2006, she worked at Indiana University Health in the United States. Upon her return, Ms. Zhang Hong engaged in clinical research and development at Parexel and QuintileIMS, where she led medical teams in designing 50 Phase I–III clinical study protocols.
Ms. Zhang Hong previously served as Clinical Development Director and China Medical Director at Pierre Fabre, and as Chief Medical Officer for Quintiles in Greater China. She drove and supported the growth of Quintiles China from 120 to 1,700 employees, and established and led multiple departments, including Medical Affairs, Clinical Trial Feasibility, Site Selection, Clinical Center Management Services, and the Center of Excellence for Clinical Research. She provided guidance on clinical trial strategy and protocol design for domestic and international pharmaceutical companies, facilitating the development and market launch of their products in China. Ms. Zhang has extensive experience in drug development strategy, planning, design, and execution in oncology and other major therapeutic areas. She also served as a member of the Clinical Research and Drug Safety Committee of the Chinese Society of Clinical Oncology (CSCO).
Let’s return to the question posed at the beginning of this article: What is the secret behind Fukang’s rapid growth? The answer lies in its “three driving forces”—“products,” “strategy,” and “talent.” Guided by the Right-6D principles in its new drug R&D strategy, Fukang has built a nearly complete R&D team and established a rich, innovatively competitive oncology pipeline. With these strengths, Fukang is accelerating its pace of development.